Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ord Shs V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is an Australia-based biotechnology company. The Company is engaged in the discovery and development of treatments for cancer and inflammation. The Company has three active drug development programs: its clinical drug candidate Veyonda, plus two technology platforms, Chroma (oncology) and Sofra (inflammation and autoimmunity), which provide the basis for the active development of a growing pipeline of drugs. Veyonda (Idronoxil) is an adjuvant therapy in chemotherapy and radiotherapy in the treatment of late-stage cancers. The Chroma drug candidates have bioactive properties, which it is exploring primarily in the anti-cancer space. Its Sofra platform is centered around short nucleic acid sequences called oligonucleotides, which can act on specific cell receptors to stop inflammation, which is a source of various debilitating and lethal diseases. It is also conducting a dose escalation and dose expansion study of NOX66 in the treatment of COVID-19 infection.


OTCPK:NOXOF - Post by User

Post by Ricky55on Apr 22, 2014 3:09pm
415 Views
Post# 22478035

Nox vs Osisko

Nox vs OsiskoIn the newspaper Journal de Montreal this morning: Article talking about the Gold Corp deal toward Osisko.At the end,the journalyst said:Osisko's total reserves of Gold is 10 millions onces .They are now at $7.70 per shares and 340 millions shares out for multi billions capitalization.
Now here is my question:Niogold has 2,1 millions reserves of gold (and probably more with the future drilling)---------approx 100 millions shares and we stand at a lousy $0.19 a shares.
On top of that,,we are  physicaly very close to the most prolific and biggest players in the region.
I am very patient and long with Niogold but i don't understand why the shares price is not around $1.00 and more at this point.Anybody have comments?
<< Previous
Bullboard Posts
Next >>